Skip to content

Author

Nidhi Shrivastava

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations

CDK4/6i selection should therefore be individualized according to toxicity profile, comorbidities, monitoring feasibility, and patient preference, with cautious interpretation of indirect comparative and real-world evidence.

Nidhi Shrivastava, Santhosh L. Gaonkar, Fayaz Shaik Mahammad · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.